Skip to content
  • Categories
  • Recent
  • Tags
  • Popular
  • Users
  • Groups
Skins
  • Light
  • Cerulean
  • Cosmo
  • Flatly
  • Journal
  • Litera
  • Lumen
  • Lux
  • Materia
  • Minty
  • Morph
  • Pulse
  • Sandstone
  • Simplex
  • Sketchy
  • Spacelab
  • United
  • Yeti
  • Zephyr
  • Dark
  • Cyborg
  • Darkly
  • Quartz
  • Slate
  • Solar
  • Superhero
  • Vapor

  • Default (No Skin)
  • No Skin
Collapse
Brand Logo

Forum

  1. Home
  2. PAAB Q&A
  3. Patient Info
  4. 411 - Is it within regulation for a pharmaceutical company to disseminate information through patient groups (as opposed to through a health care provider).
PAAB Notice
The responses, guidance, and advisories provided by the Pharmaceutical Advertising Advisory Board (PAAB), including but not limited to those available through the PAAB Forum, the PAAB website, and any PAAB correspondences, are specifically intended to assist individuals navigating the PAAB preclearance system. Repurposing or reproducing this content without written consent from the PAAB Commissioner is strictly prohibited. This prohibition includes, but is not limited to, use in machine learning or AI models.

411 - Is it within regulation for a pharmaceutical company to disseminate information through patient groups (as opposed to through a health care provider).

Scheduled Pinned Locked Moved Patient Info
1 Posts 1 Posters 202 Views
  • Oldest to Newest
  • Newest to Oldest
  • Most Votes
Reply
  • Reply as topic
Log in to reply
This topic has been deleted. Only users with topic management privileges can see it.
  • Jennifer CarrollJ Offline
    Jennifer CarrollJ Offline
    Jennifer Carroll
    wrote on last edited by
    #1

    Yes provided the patient information is non-promotional and consistent with Part III of the PM (as we’ll ensure during the PAAB review). The operative word is 'patients' (i.e. individuals who have been prescribed the medication). Keep in mind that the distribution of manufacturer sponsored patient information for prescription drugs to a broader audience (whether by manufacturer or on behalf of the manufacturer) would appear to contravene C.01.044 of the Food and Drug Regulations as these materials likely exceed the restriction to name, price, and quantity. Particularly when systematic distribution is motivated by a contractual arrangement between the manufacturer and the patient group rather than the result of medical decisions made by HCPs as they perform their professional activities in the best interest of their patients.

    1 Reply Last reply
    0
    Reply
    • Reply as topic
    Log in to reply
    • Oldest to Newest
    • Newest to Oldest
    • Most Votes


    • Login

    • Don't have an account? Register

    • Login or register to search.
    • First post
      Last post
    0
    • Categories
    • Recent
    • Tags
    • Popular
    • Users
    • Groups